期刊
CLINICAL AND EXPERIMENTAL ALLERGY
卷 50, 期 3, 页码 364-371出版社
WILEY
DOI: 10.1111/cea.13566
关键词
basophil degranulation; Fc epsilon RI; high-affinity IgE receptor; omalizumab; skin; therapy response; urticaria
资金
- Novartis Pharma B.V.
Background The pathogenesis of chronic spontaneous urticaria (CSU) and the mechanism of action of omalizumab in CSU remain unclear. Objective In this study, we assessed the responsiveness and Fc epsilon RI expression of various subsets of leucocytes in patients with CSU treated with omalizumab. Methods In this prospective cohort study, 30 patients were treated with 6 administrations of 300 mg omalizumab every 4 weeks, followed by a follow-up period of 12 weeks. Fc epsilon RI expression and the percentage of basophils, monocytes, and dendritic cell subsets were analysed before and during treatment, and after follow-up. In addition, anti-IgE- and C5a-induced basophil degranulation was measured. The results were correlated with disease activity and response to omalizumab. Results In addition to a rapid and significant reduction in Fc epsilon RI on basophils, we demonstrated a reduction in Fc epsilon RI on plasmacytoid dendritic cells during omalizumab treatment, which persisted until 3 months after discontinuation. Fc epsilon RI expression on basophils and its reduction did not correlate with the treatment response. Omalizumab led to an increased percentage of basophils in blood but not of the other Fc epsilon RI-bearing leucocytes. Basophil responsiveness was differentially affected; anti-IgE-, but not C5a-induced basophil degranulation increased during the treatment. Apart from clinical non-responders showing a stronger increase in anti-IgE-induced basophil degranulation over a period time, no differences were found in omalizumab responders vs non-responders. Conclusions/Clinical Relevance Fc epsilon RI expression on basophils decreased rapidly, while anti-IgE-induced degranulation significantly increased due to omalizumab treatment in patients with CSU, persisting at least for 3 months after stopping the treatment. None of the markers were able to predict the effectiveness of treatment. Whether basophils play a role in omalizumab responsiveness in CSU remains unclear.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据